Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBITDA Margin (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of EBITDA Margin data on record, last reported at 13.2% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 1664.0% year-over-year to 13.2%; the TTM value through Dec 2025 reached 13.99%, down 1407.0%, while the annual FY2024 figure was 28.06%, 251.0% down from the prior year.
  • EBITDA Margin reached 13.2% in Q3 2025 per AMPH's latest filing, up from 593.27% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 40.25% in Q3 2023 and bottomed at 593.27% in Q1 2025.
  • Average EBITDA Margin over 5 years is 11.12%, with a median of 22.98% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: skyrocketed 2092bps in 2023, then plummeted -62121bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 20.06% in 2021, then surged by 40bps to 28.02% in 2022, then increased by 8bps to 30.31% in 2023, then fell by -20bps to 24.2% in 2024, then plummeted by -45bps to 13.2% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 13.2% in Q3 2025, 593.27% in Q1 2025, and 24.2% in Q4 2024.